What is Spiracur?
Founded in 2007 out of the Stanford University Biodesign Innovation Program, Spiracur Inc. is headquartered in Sunnyvale, California. The company is dedicated to pioneering innovative wound healing technologies, aiming to improve patient outcomes for chronic and acute wounds. Spiracur's flagship products, the SNaP Therapy System and the ciSNaP® Closed Incision System, were developed in response to the limitations of traditional negative pressure wound therapies. These devices, featuring proprietary mechanically powered technology that operates without batteries or electricity, have received both U.S. FDA 510(k) clearance and CE Mark approval, positioning Spiracur as a key player in the medical device market for advanced wound care solutions.
How much funding has Spiracur raised?
Spiracur has raised a total of $75.5M across 4 funding rounds:
Series A
$4.2M
Series B
$20.3M
Unspecified
$35M
Debt
$16M
Series A (2007): $4.2M, investors not publicly disclosed
Series B (2009): $20.3M led by Kleiner Perkins Caufield & Byers, New Leaf Venture Partners, and De Novo Ventures
Unspecified (2011): $35M supported by De Novo Ventures, Maverick Capital, Kleiner Perkins Caufield & Byers, New Leaf Venture Partners, and Pinnacle Ventures
Debt (2014): $16M featuring GE Capital
Key Investors in Spiracur
Kleiner Perkins Caufield & Byers
Kleiner Perkins is a Menlo Park-based venture capital firm that raises dedicated funds and invests in early and growth-stage technology and lifescience companies, backing founders across consumer, enterprise, healthcare, and climate/hard tech with capital and operational support from seed through IPO or acquisition.
New Leaf Venture Partners
New Venture Partners LLC, the global venture capital firm dedicated to corporate technology spinouts, has over $700 million under management. New Venture Partners provides a bridge between technology corporations and traditional venture capital.
De Novo Ventures
De Novo Ventures is a venture capital firm focused on investing in early-stage companies within the medical device and healthcare sectors, leveraging deep industry expertise to support innovation and growth.
What's next for Spiracur?
With substantial enterprise-level backing and a recent strategic investment, Spiracur is well-positioned for its next phase of growth. The company's focus on innovative, user-friendly wound healing technologies, supported by regulatory approvals, suggests a strategic emphasis on expanding market penetration and potentially developing next-generation devices. Future capital infusions are likely to support further research and development, scaling manufacturing capabilities, and broadening commercialization efforts globally. The company's history of securing diverse funding types, from venture capital to debt, indicates a mature financial strategy aimed at sustainable expansion.
See full Spiracur company page
